scholarly journals Mycoplasma as one of causal factors of exacerbation of community-acquired pneumonia

2021 ◽  
Vol 37 (5) ◽  
pp. 5-11
Author(s):  
F. V. Shirinova
Keyword(s):  
Blood Serum ◽  
Respiratory Diseases ◽  
Mycoplasma Hominis ◽  
Community Acquired Pneumonia ◽  
Clinical Value ◽  
X Ray ◽  
Chronic Respiratory Diseases ◽  
Military Recruits ◽  
Study Results ◽  
Medical Histories

Objective. To improve the effectiveness of treatment in exacerbation of community-acquired pneumonia among military recruits with chronic inflammatory respiratory tract processes. Materials and methods. The study included the data from 266 medical histories of military recruits aged 18-26, who had community-acquired pneumonia confirmed clinically and X-ray, as well as concomitant chronic respiratory diseases and a spectrum of isolated microorganisms in the sputum. When pneumonia worsened in patients who were admitted to the hospital, the level of blood serum antibodies to M. hominis was measured. Results. The study results showed that in military recruits, suffering from community-acquired pneumonia with concomitant chronic respiratory diseases, in case of undetected microorganisms in the sputum, the measurement of blood serum IgM antibodies to Mycoplasma hominis has a clinical value. Conclusions. Mycoplasma hominis occupies a special place in the etiological structure of pathology among patients with community-acquired pneumonia.

scholarly journals Relationship between the Use of Inhaled Steroids for Chronic Respiratory Diseases and Early Outcomes in Community-Acquired Pneumonia

PLoS ONE ◽  
2013 ◽  
Vol 8 (9) ◽  
pp. e73271 ◽  
Author(s):  
Jordi Almirall ◽  
Ignasi Bolíbar ◽  
Mateu Serra-Prat ◽  
Elisabet Palomera ◽  
Jordi Roig ◽  
...  
Keyword(s):  
Respiratory Diseases ◽  
Community Acquired Pneumonia ◽  
Chronic Respiratory Diseases ◽  
Inhaled Steroids

CLINICOPATHOLOGICAL STUDY OF CHRONIC RESPIRATORY DISEASES

2021 ◽  
pp. 53-54
Author(s):  
T. Ramakoteswari ◽  
P.Venkata Kiran Kumar
Keyword(s):  
Respiratory Diseases ◽  
Lung Abscess ◽  
Age Group ◽  
Hydatid Cysts ◽  
X Ray ◽  
Chronic Respiratory Diseases ◽  
Tissue Sections ◽  
Younger Age ◽  
Clinicopathological Study ◽  
Chest X Ray

AIM: to study the spectrum of chronic respiratory diseases of lung with reference to age, gender, lifestyle and occupation. METHODS: The study is done over a period of 5 years (May 2015 to April 2020) in the Department of Pathology, KMC, Kurnool. Total of 50 lobectomy specimens were Formalin xed, parafn embedded and H & E stained tissue sections were studied. Special stains were done whenever necessary. Majority of chronic re RESULTS: spiratory diseases occured in the second to fouth decade with M:F ratio 1.38:1 . On chest x-ray majority of lung lesions affected in lower lobes. Majority of the cases clinically presented with cough, dyspnea, chestpain and fever. Among the 50 of lobectomies, bronchitectasis commonest followed by tuberculosis. CONCLUSION: outof 50 lobectomies, bronchiectasis is commonly (52%) seen followed by Tuberculosis (14%), Hydatid cysts (14%), Aspergilloma(10%), Emphysema (6%), and the least were Lung abscess (4%). In this study, majority were in the younger age group between 21-40 years.

MYCOPLASMA AND CHLAMYDIA AS ETHIOLOGICAL FACTORS OF BRONCHIAL ASTHMA IN TERMS OF ETHNOGENESIS

2013 ◽  
Vol 68 (7) ◽  
pp. 57-60
Author(s):  
O. A. Sharavii ◽  
S. V. Smirnova
Keyword(s):  
Immune Response ◽  
Chlamydia Trachomatis ◽  
Blood Serum ◽  
Bronchial Asthma ◽  
Mycoplasma Hominis ◽  
Acute Stage ◽  
Control Group ◽  
Clinical Markers ◽  
Chlamydophila Psittaci ◽  
Asthma Patients

 Aim. The study of the prevalence and clinical peculiarities of Mycoplasmosis and Chlamydiosis in patients with different pathogenic forms of bronchial asthma (BA) taking into account ethnicity of a patient. Subjects and Methods. The research covered 239 subjects – both the Europeoids and the Mongoloids in the city of Krasnoyarsk and the town of Kyzyl, all of them being BA patients of different stages, including acute stage and practically healthy. We had determined antigens Mycoplasma pneumoniae, Mycoplasma hominis, Chlamydophila pneumoniae, Chlamydophila psittaci and Chlamydia trachomatis in smears of mucosa of pharynx and antibodies to these antigens in peripheral blood serum. Results.  We found high frequency of Mycoplasmosis and Chlamydiosis in the inhabitants of Eastern Siberia, BA patients with different pathogenic forms as compared to control group. We had determined ethnic peculiarities of specific immune response: IgM to М. pneumoniae was revealed in the Europoids more frequently than in the Mongoloids, but IgM to С. pneumoniae and to C. trachomatis, C. trachomatis antigens had been revealed more often in the Mongoloids than in the Europoids. We accepted as clinical equivalents of Mycoplasmosis and Chlamydiosis diagnostics the following signs: temperature around 37C (subfebrile temperature), non-intensive but stable coughing with scanty mucous and muco-purulent sputum, dyspnea of mixed character. Conclusions. Mycoplasma and Chlamydia are meaningful etiologic factors of bronchial asthma. We have found the peculiarities of immune response depending on ethnicity of a patient (ethnic belonging). Clinical markers of Mycoplasmosis and Chlamydiosis should be taken into account in bronchial asthma in order to provide diagnostics timely as well as eradication of infection agents. Because of insufficient knowledge of problem of bronchial asthma related to contamination with Мycoplasma and Chlamydia we put the goal to study the frequency of Mycoplasmosis and Chlamydiosis occurrence in bronchial asthma patients and determine the characteristics clinical course of diseases. We defined antigens Мycoplasma pneumoniae, Мycoplasma hominis, Chlamydophila pneumoniaе, Chlamydophila psittaci, Chlamydia trachomatis in smears of oropharynx mucosa and antibodies to them in blood serum. 

CRISPR/Cas9 Genome Editing Tool: A Promising Tool for Therapeutic Applications on Respiratory Diseases

2020 ◽  
Vol 20 (5) ◽  
pp. 333-346
Author(s):  
Sadiya Bi Shaikh ◽  
Yashodhar Prabhakar Bhandary
Keyword(s):  
Respiratory Diseases ◽  
Gene Editing ◽  
Epithelial Mesenchymal Transition ◽  
Respiratory Health ◽  
Chronic Obstructive ◽  
Therapeutic Tool ◽  
Obstructive Pulmonary Disease ◽  
Mesenchymal Transition ◽  
Chronic Respiratory Diseases ◽  
Promising Tool

Respiratory diseases are one of the prime topics of concern in the current era due to improper diagnostics tools. Gene-editing therapy, like Clustered regularly interspaced palindromic repeats- associated nuclease 9 (CRISPR/Cas9), is gaining popularity in pulmonary research, opening up doors to invaluable insights on underlying mechanisms. CRISPR/Cas9 can be considered as a potential gene-editing tool with a scientific community that is helping in the advancement of knowledge in respiratory health and therapy. As an appealing therapeutic tool, we hereby explore the advanced research on the application of CRISPR/Cas9 tools in chronic respiratory diseases such as lung cancer, Acute respiratory distress syndrome (ARDS) and cystic fibrosis (CF). We also address the urgent need to establish this gene-editing tool in various other lung diseases such as asthma, Chronic obstructive pulmonary disease (COPD) and Idiopathic pulmonary fibrosis (IPF). The present review introduces CRISPR/Cas9 as a worthy application in targeting epithelial-mesenchymal transition and fibrinolytic system via editing specific genes. Thereby, based on the efficiency of CRISPR/Cas9, it can be considered as a promising therapeutic tool in respiratory health research.

From Genesis To Revelation: The Role Of Inflammatory Mediators In Chronic Respiratory Diseases And Their Control By Nucleic Acid-Based Drugs

2016 ◽  
Vol 13 (999) ◽  
pp. 1-1 ◽  
Author(s):  
Sante Di Gioia ◽  
Carla Sardo ◽  
Stefano Castellani ◽  
Barbara Porsio ◽  
Giuliana Belgiovine ◽  
...  
Keyword(s):  
Nucleic Acid ◽  
Inflammatory Mediators ◽  
Respiratory Diseases ◽  
Chronic Respiratory Diseases

Interleukin-17A: A Potential Therapeutic Target in Chronic Lung Diseases

2019 ◽  
Vol 19 (7) ◽  
pp. 921-928 ◽  
Author(s):  
Sadiya Bi Shaikh ◽  
Ashwini Prabhu ◽  
Yashodhar Prabhakar Bhandary
Keyword(s):  
Respiratory Diseases ◽  
Inflammatory Cytokine ◽  
Inflammatory Responses ◽  
Chronic Obstructive ◽  
Interleukin 17 ◽  
Potential Therapeutic Target ◽  
Chronic Respiratory Diseases ◽  
Chronic Lung Diseases ◽  
Interleukin 17A ◽  
Insight Into

Background: Interleukin-17A (IL-17A) is a pro-inflammatory cytokine that has gained a lot of attention because of its involvement in respiratory diseases. Interleukin-17 cytokine family includes six members, out of which, IL-17A participates towards the immune responses in allergy and inflammation. It also modulates the progression of respiratory disorders. Objective: The present review is an insight into the involvement and contributions of the proinflammatory cytokine IL-17A in chronic respiratory diseases like Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Distress (COPD), asthma, pneumonia, obliterative bronchiolitis, lung cancer and many others. Conclusion: IL-17A is a major regulator of inflammatory responses. In all the mentioned diseases, IL- 17A plays a prime role in inducing the diseases, whereas the lack of this pro-inflammatory cytokine reduces the severity of respective respiratory diseases. Thereby, this review suggests IL-17A as an instrumental target in chronic respiratory diseases.

Non-Communicable Diseases and Global Health Politics

2019 ◽  
pp. 626-659
Author(s):  
Roger Magnusson
Keyword(s):  
Respiratory Diseases ◽  
Communicable Diseases ◽  
World Health ◽  
Global Response ◽  
Non Communicable Diseases ◽  
Health Politics ◽  
Chronic Respiratory Diseases ◽  
Health Organization ◽  
High Level ◽  
And Control

Non-communicable diseases (NCDs), including cardiovascular disease, cancer, chronic respiratory diseases, and diabetes, are responsible for around 70 percent of global deaths each year. This chapter describes how NCDs have become prevalent and critically evaluates global efforts to address NCDs and their risk factors, with a particular focus on the World Health Organization (WHO) and United Nations (UN) system. It explores the factors that have prevented those addressing NCDs from achieving access to resources and a priority commensurate with their impact on people’s lives. The chapter evaluates the global response to NCDs both prior to and since the UN High-Level Meeting on Prevention and Control of Non-communicable Diseases, held in 2011, and considers opportunities for strengthening that response in future.

Sign in / Sign up

Export Citation Format

Share Document